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Abstract
Background: Clinical investigations are important for obtaining evidence to improve medical treatment. Large-
scale clinical trials with thousands of participants are particularly important for this purpose in cardiovascular
diseases. Conducting large-scale clinical trials entails high research costs. This study sought to investigate global
trends in large-scale clinical trials in cardiovascular diseases.
Findings: We searched for trials using clinicaltrials.gov (URL: http://www.clinicaltrials.gov/) using the key words
‘cardio’ and ‘event’ in all fields on 10 April, 2010. We then selected trials with 300 or more participants examining
cardiovascular diseases. The search revealed 344 trials that met our criteria. Of 344 trials, 71% were randomized
controlled trials, 15% involved more than 10,000 participants, and 59% were funded by industry. In RCTs whose
results were disclosed, 55% of industry-funded trials and 25% of non-industry funded trials reported statistically
significant superiority over control (p = 0.012, 2-sided Fisher’s exact test).
Conclusions: Our findings highlighted concerns regarding potential bias related to funding sources, and that
researchers should be aware of the importance of trial information disclosures and conflicts of interest. We should
keep considering management and training regarding information disclosures and conflicts of interest for
researchers. This could lead to better clinical evidence and further improvements in the development of medical
treatment worldwide.
Background
The evidence from a large number of clinical trials can
be beneficial for the medical practice of many health
care providers, informing clinical practice guidelines by
providing a rationale for determining the most appropri-
ate treatment. Accordingly, this evidence can be also
beneficial for patients by receiving the most appropriate
treatment.
Clinical trials are critical for obtaining new clinical
evidence. In cardiovascular diseases, large-scale clinical
trials involving thousands of participants are particularly
important for evaluating ther i s kr e d u c t i o n so fc a r d i a c
events and/or death, because of the requirement for the
evaluation of cardiovascular events with relatively small
differences in incidences between groups. These clinical
trials can provide important evidence about the most
appropriate treatment regimen for preventing cardiovas-
cular and metabolic diseases. In the 1970s, researchers
began to conduct large-scale clinical trials in Western
countries with the incidence of cardiovascular events as
endpoints [1,2]. The number of large-scale clinical trials
has markedly increased since then. Recently, a large
number of clinical trials for evaluating the incidence of
cardiac events and/or death using hard endpoints have
been conducted in cardiovascular and metabolic
medicine.
We reviewed important issues surrounding large-scale
clinical trials in Japan from 2007 [3,4]. The major issues
revealed by the review were the funding sources and
infrastructure surrounding of clinical trials. The review
indicated that financial and infrastructural resources
must be maintained to conduct clinical trials appropri-
ately. However, high research costs are involved in
clinical trials. Currently, clinical trials receive funding
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any medium, provided the original work is properly cited.from various sources, including public agencies, private
companies, foundations, etc. It has been proposed that
industry-funded trials may be more likely to produce
biased results, interpretations and conclusions [5-11].
Ridker, et al. reported that cardiovascular trials reported
between 2000 and 2005 funded by for-profit organiza-
tions were more likely to report positive findings than
those funded by not-for-profit organizations [5].
Considering this situation, it is important to clarify the
problems and solutions surrounding current large-scale
clinical trials. Thus, in this study we sought to elucidate
the current situation and important global trends in
large-scale clinical trials examining cardiovascular
diseases.
Methods
We searched for trials using clinicaltrials.gov (URL:
http://www.clinicaltrials.gov/) with the words ‘cardio’ or
‘event’ in all fields on 10 April 2010. We then selected
all large-scale clinical trials examining cardiovascular
diseases. We defined ‘large-scale clinical trials’ as trials
involving 300 participants or more. If the trial was on-
going and the planned number of participants was 300
or more, this trial was regarded as a ‘large-scale clinical
trial’. We defined ‘trials examining cardiovascular dis-
eases’ as trials where the primary endpoint was the inci-
dence of cardiovascular events, e.g. myocardial
infarction, chronic heart failure, ischemic heart attack,
and/or mortality including death.
For the target trials, we recorded 11 items: 1) primary
objective of trial, 2) trial design, 3) interventions, 4)
sponsor(s), 5) starting year and month, 6) ending year
and month, 7) number of enrolled participants or target
number of participants, 8) countries of trial sites, 9)
results of trial, 10) publications linked from clinicaltrials.
gov, 11) funding sources.
We categorized the trials by each criterion, and calcu-
lated summary statistics. The relationship between fund-
ing sources (industry or non-industry) and the results of
a primary analysis (positive or negative) were tested
using 2-sided Fisher’s exact tests. A result was regarded
as positive if a trial met the primary objective of statisti-
cally significant superiority or non-inferiority over con-
trol conditions or behavioral interventions.
Results
Screening of large-scale clinical trials in cardiovascular
diseases
We showed the number of trials during screening of the
trials in Figure 1. We found 2,058 trials registered in
clinicaltrials.gov with the words ‘cardio’ or ‘event’ in all
fields as of 10 April, 2010. Of 2,058 trials, 787 met the
criterion of involving 300 participants or more. Of these
787 trials, 344 met the criteria that the primary
endpoint of the trial was the incidence of cardiovascular
events and the trial population was patients with cardio-
vascular diseases.
None of these 344 trials were excluded from our ana-
lysis because of insufficient information.
Trial design (RCT/non-RCTs) and number of participants
We categorized all 344 trials according to the trial
design and the number of participants (Table 1). Of
these trials, 71% (243/344) were randomized controlled
trials (RCTs), and 29% (101/344) were not RCTs (non-
RCTs). Examining the number of participants revealed
that 0.6% (2/344) of the trials involved 100,000 partici-
pants or more, 2% (6/344) of trials involved between
30,000 and 99,999 participants, 12% (42/344) involved
between 10,000 and 29,999 participants, and 35% (121/
344) of trials involved less than 1,000 participants. The
results revealed a trend towards an association between
smaller proportion of trials and larger numbers of parti-
cipants. The statistical significance of this trend was not
tested because of small sample sizes.
In trials involving between 3,000 and 9,999 partici-
pants, and those involving between 10,000 and 29,999
participants, the proportions of RCTs were 82% and
88%, respectively. In trials involving less than 1,000
Figure 1 Screening of trials. CV: cardiovascular
Table 1 Numbers of trials by number of participants and
trial design (RCT or Non-RCT)
Number of
participants
Number of trials Proportion of RCT
(%)
RCT Non-
RCT
Total
≥100,000 0 2 2 (0.6%) 0
30,000-99,999 2 4 6 (1.7%) 33.3
10,000-29,999 37 5 42 (12.2%) 88.1
3,000-9,999 56 12 68 (19.8%) 82.4
1,000-2,999 72 33 105 (30.5%) 68.6
< 999 76 45 121 (35.1%) 62.8
Total 243 101 344 (100%) 70.6
RCT: randomized controlled trial; Non-RCT: non-randomized controlled trial
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2,999 participants, the proportion that were RCTs was
63% and 69%, respectively. These proportions were sub-
stantially lower for trials involving between 3,000 and
29,999 participants.
Number of trials by starting year
We categorized the numbers of trials according to the
starting year (Figure 2). The number of large-scale clini-
cal trials increased gradually from the latter 1990s, and
showed a 2.4-fold increase in 2003 relative to 2002.
Fifty-nine trials were registered with clinicaltrials.gov in
2009. This was the highest number of all the years we
examined. It should be noted that the number of trials
reported for 2010 includes trials registered before 10
April, 2010.
A larger proportion of trials were RCTs before 2000,
relative to after 2000. Conversely, the number of non-
RCTs increased after 2000. From 2005, the trend of the
increasing number of non-RCTs became more obvious,
although number of RCTs has not changed noticeably
during this period.
Number of trials by funding sources
We categorized trials according to the category of fund-
ing sources; industry, academic, government, foundation,
and other. We found that 204 trials (59%) were funded
by industry (e.g. pharmaceutical companies or medical
device providers), 122 trials (35%) were funded by aca-
demic organizations, e.g. universities and research cen-
ters, 55 trials (16%) were funded by governmental
organizations, 32 trials (9%) were funded by foundations,
48 trials (14%) were funded by other organizations (e.g.
hospitals and individuals), 97 trials (28%) were funded
by multiple funding organizations, and 17 trials (5%)
were funded by both governmental organizations plus
industries or foundations (Table 2).
We analyzed the relationship between starting years of
trials, types of funding sources, and the numbers of par-
ticipants (Figure 3). ‘Public’ funding sources included
governmental organizations, and ‘Private’ sources
included industry, academic institutions, foundations,
and others.
Trials with larger numbers of participants were mainly
conducted with funding from private sources.
Summary statistics of the numbers of participants
according to funding sources are shown in Table 3. The
median of number of participants in publicly funded
trials was 2,331, and that in trials with combined fund-
ing sources was 2,450. The median number of partici-
pants in privately funded trials was 1,400, substantially
lower than publicly funded trials and trials with com-
bined funding sources.
Number of trials by region or country
We calculated the number of trials with multiple partici-
pating countries according to the starting year of trials
(Table 4). The results showed that 227 trials (68%) were
conducted in a single country, while 106 trials (32%)
were conducted in multiple countries. The number of
trials conducted in single country showed a 7.1-fold
increase between 2006 and 2010 compared with those
conducted before 2000, although those conducted in
multiple countries showed a 3.1-fold increase by the
2006-2010 period compared with those conducted
before 2000. The number of trials involving more than
20 countries from 2001-2005 and from 2006-2010 was
16 and 17, respectively, and one trial involving more
than 20 countries was conducted before 2000.
We investigated the regions involved and starting year
in each trial. 171 trials (51%) were in Western Europe,
w h i c hw a st h em o s tf r e q u e n t l yi n v o l v e dr e g i o n .1 6 1
trials (48%) were conducted in North America, 95 trials
(28%) were in East Asia. Only 32 trials (10%) were in
Africa and 33 (10%) were in Southeast Asia. Until 2000,
North America and Western Europe were the only
major regions involved in large-scale clinical trials.
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Figure 2 Trends in the number of trials by starting year and
trial design (RCT or non-RCT).
Table 2 Numbers of trials by funding source and trial
design (RCT or non-RCT)
Funding
source
Number of trials Proportion of RCT
(%)
RCT Non-
RCT
Total
Industry 142 62 204 (59.3%) 69.6
Academic 79 43 122 (35.5%) 64.8
Government 44 11 55 (16.0%) 80.0
Foundation 28 4 32 (9.3%) 87.5
Other 37 11 48 (14.0%) 77.1
Total 243 101 344 (100%) 70.6
Sawata and Tsutani BMC Research Notes 2011, 4:222
http://www.biomedcentral.com/1756-0500/4/222
Page 3 of 6Between 2006 and 2010, however, East Asia became a
major region of involvement.
Relationship between results and funding sources
In 83 (24%) RCTs whose results were disclosed, we
counted the number of trials according to the primary
result and funding source. Trial results with parallel
group comparisons were grouped into two categories,
positive and negative, according to the statistical super-
iority or non-inferiority relative to control, revealed by
primary analysis.
Thirty of 55 (55%) industry-funded trials and seven of
28 (25%) non-industry funded trials showed statistical
superiority or non-inferiority to control. Forty-six (55%)
trials failed to meet the primary objective. The relation-
ship between trial results and funding sources was
statistically significant (p = 0.012, 2-sided Fisher’s
exact test).
Figure 3 Dot plot by starting year, funding source, and number of participants.
Table 3 Summary statistics regarding numbers
of participants by funding source
Parameter Public Private Combined Total
Number of trials (N) 19 289 36 344
Number of participants
≥100,000 0 2 0 2
30,000-99,999 1 4 1 6
10,000-29,999 1 38 3 42
3,000-9,999 6 51 11 68
1,000-2,999 6 88 11 105
< 999 5 106 10 121
Mean 4,696 5,944 4,703 5,745
Standard deviation 8,877 21,485 7,299 19,934
Median 2,331 1,400 2,450 1,555
Max 39,876 300,000 40,000 300,000
Table 4 Number of participating countries by starting
year of trials
Number of countries Number of trials (N = 333*)
-2000 2001-2005 2006-2010 Total
Single country 19 73 135 227 (68.2%)
Multiple countries 16 40 50 106 (31.8%)
2-5 countries 8 14 13 35 (10.5%)
6-20 countries 7 10 20 37 (11.1%)
> 20 countries 1 16 17 34 (10.2%)
* 11 trials whose starting years or countries were unknown were excluded.
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We found 344 trials involving 300 or more participants
that were registered with clinicaltrials.gov, using the
search terms ‘cardio’ and ‘event’ in any field. All of the
selected trials were conducted to evaluate the incidence
of cardiovascular events and/or death in cardiovascular
diseases.
Of 344 trials, more than 70% were RCTs, and 15% of
trials enrolled more than 10,000 participants. In trials
involving between 3,000 and 9,999 participants, and
those involving between 10,000 and 29,999 participants,
the proportion of trials that were RCTs was greater than
0.8, substantially higher than the proportion of RCTs
among trials involving less than 3,000 participants.
We categorized the number of trials by starting year.
The number of large-scale clinical trials increased gra-
dually from the latter 1990s, and showed 2.4-fold
increase in 2003 compared with 2002. From 2003, num-
ber of non-RCTs increased obviously. This increase was
considered to be related to the International Committee
of Medical Journal Editors’ (ICMJE) request for the
registration of trials that began enrolling participants
a n yt i m eb e f o r eJ u l y1 ,2 0 0 5 ,if investigators wished to
submit the results of their trial to journals that follow
ICMJE policy [12,13]. This requirement might have
increased investigators’ awareness of the importance of
trial registration. Fifty-nine trials registered with clinical-
trials.gov started in 2009. It should be noted that the
number of trials reported for 2010 includes those regis-
tered before 10 April, 2010. The number of trials regis-
tered with clinicaltrials.gov has thus steadily increased.
Regarding funding sources, about 60% of trials were
funded by private industry, e.g. pharmaceutical compa-
nies or medical device providers, 28% were funded by
multiple funding organizations, and 5% were funded by
a combination of governmental organizations and indus-
tries or foundations. These results revealed that various
organizations funded large-scale clinical trials, and spon-
sors sometimes required multiple funding sources to
conduct large-scale clinical trials. When we examined
the 50 trials with 10,000 participants or more, 40 trials
(80%) were found to be funded by industry (or industry
plus other organizations), while six trials (12%) were
funded at least partially by governmental organizations,
and only two trials (4%), both started in the 1990s in
the United States, were solely funded by governmental
o r g a n i z a t i o n ss u c ha st h eN a t i o n a lH e a r t ,L u n g ,a n d
Blood Institute (NHLBI).
Our examination of the relationship between the types
of funding sources and participant numbers revealed
that the median number of participants involved in pri-
vately funded trials was lower than that involved in pub-
licly funded trials and trials with combined funding. On
the other hand, the mean and maximum of numbers of
privately funded trials were higher than for publicly
funded trials and trials with combined funding sources.
Trials with larger numbers of participants were mainly
conducted with funding from private sources, although
there were also a large number of smaller trials funded
by private sources. These findings indicate that it is rela-
tively difficult to conduct large-scale clinical trials
funded solely by governmental organizations.
According to the records in clinicaltrials.gov, 26 of
344 trials (8%) did not disclose their planned ending
years. Of 308 trials whose ending years were disclosed,
127 trials have been completed by the end of 2009.
However, in September 2010, the results of only 77
trials (61%) commenced before 2009 were accessible,
and the results of 50 trials (39%) were not disclosed. In
other words, we could not access to the ending years or
results of 76 trials (22%). This result indicates that some
sponsors did not update the registered information in
clinicaltrials.gov.
In 83 RCTs where publications were disclosed, 55% of
industry-funded trials and only 25% of non-industry
funded trials reported statistically significant superiority
of the target intervention relative to control. This differ-
ence was statistically significant (p = 0.012, 2-sided Fish-
er’s exact test), indicating that industry-funded trials
were significantly more likely to report statistically sig-
nificant differences favoring target interventions com-
pared with references. This result is consistent with the
findings of previous reports [5-11], showing that indus-
try-funded trials tended to produce results in favor of
target interventions compared with references.
It should be noted that more than half of the trials
failed to meet the primary objective. This means not
only sacrifices in terms of the voluntary cooperation of
participants, but also represents the wasting of limited
resources. This finding suggests that sponsors should
discuss the rationale of their study design and sample
size in detail before trials begin. Conducting small pilot
trials may provide an appropriate solution for avoiding
unsuccessful trials. The involvement of independent
data monitoring committees, including third party bios-
tatisticians, may be another worthwhile solution. In
addition, sponsors should stop or modify the trial when
blinded interim analysis indicates that there is a strong
possibility the primary objective will not be achieved. A
greater number of worthwhile trials will be possible if
the waste of resources by failed trials is reduced.
The current study suffers from the limitation that all
data were obtained from clinicaltrials.gov, which is run
by NIH in United States. As such, clinical trials in
which the United States was not involved may have
been omitted.
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Our research revealed that number of large-scale clinical
trials in cardiovascular diseases increased steadily over
time, and that clinical trials are becoming increasingly
globalized. This indicates that the quality and quantity
of evidence is improving. However, sponsors should
aware that the timely update of the registered trial infor-
mation in clinicaltrials.gov is important.
Our findings highlight a concern about the potential
bias related to funding sources. More than 80% of the
trials we found were conducted by private funding
sources, especially clinical trials with larger numbers of
participants. Therefore, sponsors as well as researchers
at each site should be aware of the importance of con-
flicts of interest. The ICMJE requests that sponsors dis-
close certain information regarding the trial
management, including funding sources. We should
keep considering management and training regarding
conflicts of interest. Sponsors should also be aware that
minimizing the waste of resources by careful considera-
tion of their study designs is also one of their responsi-
bilities as sponsor.
Addressing these issues may facilitate the improve-
ment of the quality of clinical evidence, and the devel-
opment of better medical treatment worldwide.
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